Clinical trials: Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
A Study of TAVO101 in Atopic Dermatitis Patients
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
- Trial name
- NCT06176040
- Testing
- TAVO101
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Tavotek Biotherapeutics
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy, Chronic Rhinosinusitis With Nasal Polyps
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with…
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Trial name
- NCT02743871
- Testing
- PF-06817024
- Where
- 20 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at…
- Trial name
- ROCKET-SHUTTLE (NCT05724199)
- Testing
- Rocatinlimab
- Where
- 234 sites in United States, Argentina and 24 more
- Volunteers
- 746 people
- Sponsor
- Amgen
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05240300
- Testing
- BX005-A
- Sponsor
- BiomX, Inc.
Moderate to Severe Atopic Dermatitis
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT07370909
- Testing
- LW402
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Dermatitis Atopic
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
- Trial name
- ATLANTIS (NCT05769777)
- Testing
- Amlitelimab
- Where
- 174 sites in United States, Argentina and 23 more
- Volunteers
- 999 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis, Atopic Eczema
A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis
Rationale (What is the reason for this study?) Atopic dermatitis (AD) is a condition that makes the skin dry and itchy and is the most common skin condition that causes redness and irritation.
- Trial name
- ADaggio (NCT07479615)
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
A Study Evaluating APG777 in Atopic Dermatitis
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
- Trial name
- NCT06395948
- Testing
- APG777
- Where
- 94 sites in United States, Canada and 7 more
- Volunteers
- 470 people
- Sponsor
- Apogee Therapeutics, Inc.
Eczema, Atopic Dermatitis
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic…
- Trial name
- STREAM-AD (NCT05131477)
- Testing
- Amlitelimab
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 390 people
- Sponsor
- Kymab Limited
Atopic Dermatitis
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
The purpose of this trial is to test if treatment with the trial drug, tralokinumab, can affect the body's immune response to vaccines.
- Trial name
- ECZTRA 5 (NCT03562377)
- Testing
- Tralokinumab, Tdap vaccine, Meningococcal vaccine
- Where
- 51 sites in United States, Canada
- Volunteers
- 215 people
- Sponsor
- LEO Pharma
Atopic Dermatitis (AD)
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, oozing and crusting, redness, skin erosion and dry skin.
- Trial name
- NCT04666675
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.
- Trial name
- JADE TEEN (NCT03796676)
- Testing
- PF-04965842, PF04965842
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 287 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04626297
- Testing
- Lebrikizumab
- Where
- 85 sites in United States
- Volunteers
- 254 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
- Trial name
- NCT07582237
- Where
- South Korea
- Volunteers
- 262 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
- Trial name
- NCT05186922
- Testing
- CM326
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Keymed Biosciences Co.Ltd
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer